May. 6 at 6:37 AM
$MREO no comment by Ultragenyx on Setrusumab during conference call. Still in the back of Corporate Deck you can find the information. Good news, as they are not stopping efforts, so they see chances to get an alignment with FDA, most likely for children and/or subgroups. Asset is alive, and as is not considered in the valuation, positiv news could skyrocket share price from low levels. Let‘s see what Mereo teils us during Q1 call next week on alvelestat and setrusumab. After Partnering Alvelestat and in case of way forward for setrusumab, I see chances of buyout by Ultragenyx. Not only interesting because of Setrusumab, but also Vantictumab EU rights could bolster Ultragenyx bone disease business and create synergies with existing setup. And they aviod milestone and royalty payments with low risk / valuation.
